Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 65

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 65
---
 our compensation & people committee reviews and evaluates, with input from our chief executive officer (other than with respect to himself), the need for adjustment of the base salaries of our NEOs based on changes and expected changes in the scope of a NEO’s responsibilities, 47

including promotions, the individual contributions made by and performance of the NEO during the prior year, the NEO’s performance over a period of years, overall labor market conditions, the relative ease or difficulty of replacing the executive with a well-qualified person, our overall growth and development as a company and general salary trends in our industry and among our peer group and where the NEO’s salary falls in the salary range presented by that data. In making decisions regarding salary increases, the compensation & people committee may also draw upon the experience of members of our board of directors with other companies. In February 2024, based on a review of market data provided by Aon and the factors described above, including the current compensation levels of our NEOs and company performance and individual contributions, our compensation & people committee or board of directors, as applicable, approved 2024 salary increases for our NEOs. The 2023 and 2024 annual base salaries of each of our NEOs were:

|                            |     | 2023            
 Base Salary ($) |         |     | 2024            
 Base Salary ($) |         |     | % Change |   |      |
| Brian Goff                 |     |                 | 798,250 |     |                 | 822,198 |     |          | 3 | %(1) |
| Cecilia Jones              |     |                 | 484,500 |     |                 | 503,880 |     |          | 4 | %(2) |
| James Burns                |     |                 | 497,007 |     |                 | 511,917 |     |          | 3 | %(1) |
| Sarah Gheuens, M.D., Ph.D. |     |                 | 566,500 |     |                 | 583,495 |     |          | 3 | %(1) |
| Tsveta Milanova            |     |                 | 510,000 |     |                 | 525,300 |     |          | 3 | %(1) |

| (1) | Increase reflects merit-based adjustment. |

| (2) | Increase reflects merit- and market-based adjustments. |

Annual Performance-based Cash Incentives We have designed our annual performance-based cash